Expert Insights on Emerging Data from the 2014 Global Congress on
MS
Current Clinical Data on New and Emerging
MS Disease-Modifying Therapies
Glatiramer Acetate
Pegylated Interferon
Daclizumab HYPMRI Results
You must view all 3 sections of this activity to earn CME credit.
Please click on the next section title to continue.
Biomarkers, Safety, and New Treatment Targets
MS Therapy Is Cost-effective
Biomarkers of Treatment ResponseAnalysis by Dhib-Jalbut
Biomarkers of Treatment ResponseAnalysis by Dhib-Jalbut (cont)
NatalizumabStopping Treatment
Natalizumab (cont) PML
Natalizumab (cont)Extended Dosing
PML Risk With Other DMTs
MS Management Algorithms
You must view all 3 sections of this activity to earn CME credit.
Please click on the next section title to continue.
RemyelinationAnti-LINGO
RemyelinationHistamine 3 Receptor Agonist
Other Therapies on the Horizon
Other Therapies on the Horizon (cont)
Abbreviations (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)
References (cont)